10-K: Nexentis Shifts Focus to Biotech, Renewables Amid Losses

Nexentis Technologies Inc. reported a reduced net loss in 2025, driven by strategic divestitures and new ventures in oncology biotechnology and solar energy, despite ongoing operating losses and a going concern warning.

Summary

• Nexentis Technologies Inc. (formerly N2OFF, Inc.) has undergone a significant strategic shift, divesting its former food tech and N2O emissions businesses to focus on oncology biotechnology and renewable energy projects.
• The company reported a total net loss of $4,156,000 for the year ended December 31, 2025, an improvement from $5,347,000 in 2024.
• Net loss attributable to the company's stockholders was $4,004,000 in 2025, compared to $5,193,000 in 2024.
• Operating loss increased to $4,230,000 in 2025 from $3,283,000 in 2024, primarily due to increased research and development and general and administrative expenses.
• Research and development expenses rose to $179,000 in 2025, up from $0 in 2024, following the acquisition of MitoCareX Bio Ltd. in October 2025.
• General and administrative expenses increased by 56% to $5,109,000 in 2025, mainly due to higher share-based compensation and professional/legal fees.
• Cash and cash equivalents increased to $3,832,000 as of December 31, 2025, from $1,923,000 in 2024, largely from financing activities.
• The company's accumulated deficit grew to $38,557,000 as of December 31, 2025.
• A 1-for-35 reverse stock split was effected on September 22, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
• The company acquired 100% of MitoCareX Bio Ltd., an Israeli drug discovery company focused on cancer and inflammatory metabolic diseases, for approximately $8,864,000 in cash and stock.
• Nexentis entered a joint venture to finance two battery storage projects in Sicily, Italy, and continues to invest in solar photovoltaic (PV) projects in Europe through Solterra Renewable Energy Ltd.
• The company sold its 98% stake in Save Foods Ltd. to Voice Assist, Inc. on March 15, 2026, for Voice Assist common stock and future cash/royalty considerations.
• Management believes existing capital resources are sufficient to fund operations through the first quarter of 2027, but there is substantial doubt about the company's ability to continue as a going concern.
• The company continues to face risks related to its early-stage development in biotechnology, intense competition in renewable energy, and geopolitical instability in Israel.
• As of March 31, 2026, there were 5,111,362 shares of common stock outstanding.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to the explicit 'going concern' warning, increasing operating losses, and the early, unproven nature of its new core businesses, despite a reduction in overall net loss and successful capital raises.

Positives

• Net loss attributable to stockholders decreased to $4,004,000 in 2025 from $5,193,000 in 2024, indicating an improvement in overall profitability.
• Total net loss decreased by 22% to $4,156,000 in 2025 from $5,347,000 in 2024.
• Cash and cash equivalents increased significantly to $3,832,000 as of December 31, 2025, from $1,923,000 in 2024, bolstered by financing activities.
• Working capital improved to $4,580,000 in 2025 from $2,560,000 in 2024.
• The acquisition of MitoCareX Bio Ltd. provides a new strategic focus on oncology biotechnology with a platform-based drug discovery approach (MITOLINE algorithm) targeting significant market opportunities in lung and pancreatic cancer.
• The company's expansion into renewable energy projects, including solar PV and battery storage in Italy, Poland, and Germany, diversifies its business model.
• Successful capital raises through standby equity purchase agreements, a PIPE agreement, and warrant exercises provided $8,856,000 in financing activities during 2025.
• The company recognized a gain of $1,136,000 from the change in fair value of contingent consideration related to the MitoCareX acquisition.
• The company recognized an income tax benefit of $18,000 in 2025, primarily due to a reduction in deferred tax liabilities related to intangible asset amortization from the MitoCareX acquisition.

Negatives

• The company has a history of significant operating losses, with an accumulated deficit of $38,557,000 as of December 31, 2025.
• Operating loss increased to $4,230,000 in 2025 from $3,283,000 in 2024, indicating worsening operational performance.
• Research and development expenses increased to $179,000 in 2025 from $0 in 2024, reflecting the costs associated with the early-stage MitoCareX acquisition and its development programs.
• General and administrative expenses increased by 56% to $5,109,000 in 2025, driven by higher share-based compensation and professional/legal fees.
• Financing expenses, net, increased significantly to $1,545,000 in 2025 from $252,000 in 2024.
• The company's investment in Plantify Foods Inc. was fully written off as of December 31, 2025, due to lack of an active market and deterioration of Plantify's financial condition, including the insolvency of its operating subsidiary.
• MitoCareX Bio Ltd. is an early-stage drug discovery company with a limited operating history, no products approved for commercial sale, and no revenue generated from product sales to date, incurring net losses of $1,394,000 in 2025.
• MitoCareX withdrew provisional patent applications in February 2025 because scientific results did not support prosecution, indicating potential setbacks in intellectual property protection for its lead compound.
• The company faces substantial doubt about its ability to continue as a going concern, with existing capital projected to last only through the first quarter of 2027.
• The reverse stock split of 1-for-35 on September 22, 2025, was necessary to regain Nasdaq compliance, often a sign of underlying stock price weakness.

Risks

• The company has a history of operating losses and expects to incur additional losses in the future, with an accumulated deficit of $38,528,000 as of December 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern, as existing capital is only projected to fund operations through Q1 2027.
• The company may need to raise significant additional capital, which may not be available on acceptable terms or at all, potentially forcing delays or termination of development programs.
• Unsuccessful integration of current and/or future acquisitions (like MitoCareX) or joint ventures (like Solterra) could disrupt business activities and adversely affect results.
• MitoCareX's limited operating history, lack of revenue, and history of operating losses pose significant risks to the company's financial results.
• Delays or failures in MitoCareX's early-stage pipeline, including its chemical scaffold and MITOLINE algorithm, could materially harm the business.
• Reliance on third parties for key aspects of MitoCareX's development, manufacturing, and clinical activities could increase costs and delay or prevent commercialization.
• The company is subject to risks related to portfolio concentration, particularly with its new focus areas.
• Operating results may fluctuate, making them difficult to predict and potentially causing results to fall short of expectations.
• International expansion exposes the company to business, regulatory, political, operational, financial, and economic risks.
• Inability to secure and maintain patent or other intellectual property protection for products and technologies could harm the company's ability to compete.
• Failure to prevent unauthorized use or disclosure of proprietary trade secrets and unprotected know-how could harm competitiveness.
• Potential patent and other intellectual property litigation could be costly, divert management's attention, and require payment of damages or discontinuation of product sales.
• Claims challenging the inventorship or ownership of patents and other intellectual property could arise.
• The company's investment in the solar energy sector may not realize a return on investment.
• Climate-related risks, such as extreme weather conditions, may adversely affect Solterra's business and the joint venture value.
• Regulatory and compliance changes in the renewable energy sector may adversely impact Solterra's operations and joint venture value.
• Permitting and licensing delays may impact Solterra's project timelines and joint venture value.
• Fluctuations in electricity tariffs may impact Solterra's revenue and joint venture value.
• Supply chain and contractor disruptions may delay Solterra's projects and affect joint venture value.
• Equipment malfunctions and downtime may impact Solterra's operations and joint venture value.
• Intense competition in the renewable energy sector may affect Solterra's market share and joint venture value.
• Joint venture and partnership risks, including disputes or financial difficulties of partners, may affect Solterra's projects and joint venture value.
• Safety and operational risks associated with renewable energy projects may impact Solterra's business and joint venture value.
• The evolution of the business strategy may not be successful and may require additional financing or incur increased operational costs.
• Conditions in Israel, including ongoing conflicts and political instability, may adversely affect operations and limit the ability to market products.
• Difficulty in enforcing covenants not-to-compete under Israeli law could result in added competition.
• Difficulty in acquiring jurisdiction and enforcing liabilities against officers and directors based in Israel.
• Failure to comply with Nasdaq Capital Market listing requirements could lead to delisting.
• The market price of common stock may be highly volatile.
• Sales of a substantial number of shares by existing stockholders could depress the market price.
• Additional capital raises through equity or debt could result in dilution to stockholders.
• Nevada law and corporate provisions could make a merger, tender offer, or proxy contest difficult, depressing stock price.
• The company may be subject to securities litigation, which is expensive and diverts management attention.
• Disruptions to information technology systems due to cyber-attacks or failure to upgrade systems may impair operations.
• Failure to comply with anti-bribery, anti-corruption, and anti-money laundering laws could lead to penalties.
• Increased costs and management time are required due to Nasdaq listing and compliance initiatives.
• Risks related to compliance with corporate governance laws and financial reporting standards.
• The ongoing conflict in Ukraine may result in market volatility that could adversely affect the business.
• Failure to implement and maintain effective internal control over financial reporting could lead to inaccurate financial results.

Future Outlook

The company expects to continue incurring significant net losses for the foreseeable future as it advances its oncology biotechnology and renewable energy development programs. Management believes existing capital resources will be sufficient to fund operations through the first quarter of 2027, but additional financing will be required for continued growth and strategic initiatives. The success of MitoCareX's ACSMT programs and MITOLINE algorithm, as well as the commercialization of renewable energy projects, are critical for future revenue generation, which is not expected for many years, if at all.

Management Comments

• Management's current views with respect to future events and financial performance are reflected in forward-looking statements, which are not guarantees of future performance and involve risks and uncertainties.
• We believe that our assumptions are based upon reasonable data derived from and known about our business and operations.
• We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results over time except as required by law.
• Management currently is of the opinion that its existing cash will be sufficient to fund operations through the first quarter of 2027.
• Management plans to continue securing sufficient financing through the sale of additional equity securities or capital inflows from strategic partnerships.

Industry Context

StockSavvy.ai notes that Nexentis Technologies Inc.'s strategic pivot into oncology biotechnology and renewable energy aligns with two high-growth, innovation-driven sectors. The oncology market, particularly for non-small cell lung cancer and pancreatic cancer, presents substantial unmet needs and significant market opportunities, with the global lung adenocarcinoma treatment market projected to reach $6.08 billion in 2024 and grow at a CAGR of 10.7% to 2030. Similarly, the global mitochondria-based therapies market is expected to grow to $779.4 million by 2032, and the protein structure analysis market to $2.5 billion by 2030. The renewable energy sector, especially solar PV and battery storage, is experiencing robust growth, with Italy targeting 80 GW of solar power and 7.5-8.5 GW of BESS capacity by 2030. However, both industries are characterized by intense competition, high R&D costs, and regulatory complexities, which Nexentis, as an early-stage player, must navigate effectively.

Comparison to Industry Standards

• MitoCareX's focus on targeting the SLC25A protein family for cancer and inflammatory metabolic diseases is a novel approach, as there are currently no FDA-approved drugs specifically targeting this protein family, differentiating it from competitors like Relay Therapeutics (Dynamo platform), Daiichi Sankyo (Patritumab deruxtecan), and Scorpion Therapeutics (STX-241, an EGFR inhibitor).
• The company's MITOLINE algorithm for 3D protein modeling aims to overcome limitations in existing AI-based systems and template availability, a critical differentiator in the growing $1.26 billion protein structure analysis market.
• In the renewable energy sector, Solterra's strategy of selling projects at various development stages is common, but its market share in Italy, Poland, and Germany is currently not significant compared to larger global and local competitors.
• Italy's NECP targets a 58% reduction in emissions by 2030 and a significant increase in solar and battery storage capacity (80 GW solar, 7.5-8.5 GW BESS by 2030), providing a favorable regulatory backdrop for Solterra's projects, aligning with broader European green energy initiatives.

Corporate Governance

Legal Proceedings

• There are no pending legal proceedings to which the company is a party or in which any director, officer, or significant shareholder has an adverse material interest.

Related Party Transactions

• Alon Silberman, CEO of MitoCareX (a wholly-owned subsidiary), is the brother of Kfir Silberman, owner of L.I.A. Pure Capital Ltd., a 5% stockholder and lender to the company.
• Amitay Weiss (Chairman of the Board) and Liat Sidi (Director) also serve as board members of SciSparc Ltd., one of the sellers in the MitoCareX acquisition.
• Amitay Weiss also serves as a member of the board of directors of Solterra Energy, the parent company of Solterra Renewable Energy Ltd., with which the company has loan and partnership agreements.
• The company acquired 267,000 shares of Solterra Energy in 2024 for approximately $219,000.
• The company entered into a facility agreement with L.I.A. Pure Capital Ltd. on October 1, 2024, for up to €6,000,000, and issued a five-year warrant to purchase 52,858 shares of common stock.
• From January 1, 2024, through March 3, 2026, the company issued an aggregate of 230,000 shares to Pure Capital for consulting services.
• The company entered into multiple loan agreements with MitoCareX and L.I.A. Pure Capital Ltd. in 2024 and 2025, with Pure Capital guaranteeing repayment of a $372,000 loan to MitoCareX.

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises and the potential for further stock price volatility due to the company's early-stage ventures and going concern uncertainty.
• Employees and management are subject to the risks of an early-stage company, including potential workforce reductions if additional capital is not secured, but key personnel are incentivized through equity grants.
• Customers in the biotechnology and renewable energy sectors could benefit from innovative solutions if MitoCareX's drug candidates are successfully developed and Solterra's projects are commercialized.
• Creditors face elevated risk due to the company's accumulated deficit and going concern warning, although some loans are secured or guaranteed by related parties.
• Regulatory bodies will continue to scrutinize the company's compliance with SEC and Nasdaq listing requirements, as well as industry-specific regulations in biotech and renewable energy.

Next Steps

• Continue to secure sufficient financing through the sale of additional equity securities or capital inflows from strategic partnerships.
• Advance MitoCareX's hit-to-lead medicinal chemistry campaign to optimize hit compound 1 and perform further in-vitro efficacy evaluations.
• Routinely perform new virtual and in-vitro screenings to recognize additional chemical scaffolds as potential anti-cancer therapeutics.
• Test developed compounds in a dedicated preclinical setting for NSCLC patients with EGFR mutated backgrounds (standalone or combination with TKIs) and in combination with platinum-based chemotherapy.
• Optimize the MITOLINE algorithm using ensemble docking and/or molecular dynamics-based methods.
• Commercialize MITOLINE through licensing and strategic partnerships, including upfront payments, milestone-linked revenues, and royalty fees.
• Continue to collaborate with Solterra in surveying the European solar energy market for additional projects.
• Manage and integrate the PV joint venture with Solterra and any future joint ventures.
• Monitor and address the impact of regional security conditions in Israel on operations.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about our ability to continue as a going concern' and projects that existing capital will only last through Q1 2027. This fundamental uncertainty, coupled with increasing operating losses, an accumulated deficit of over $38 million, and the early, unproven nature of its new core businesses (biotechnology and renewable energy), presents an extremely high-risk profile. While the net loss decreased and cash reserves increased due to financing activities, these are temporary measures. The withdrawal of patent applications for its lead biotech compound and the write-off of a significant investment in Plantify further underscore the challenges. The stock has already undergone a 1-for-35 reverse split to maintain Nasdaq listing, indicating prior significant share price weakness. Given these severe financial and operational risks, a seasoned investor would likely recommend a strong sell to avoid potential significant capital loss.

Keywords

Oncology Biotechnology, Renewable Energy, Solar PV, Drug Discovery, NSCLC, Pancreatic Cancer, Mitochondrial Carriers, MITOLINE, SEC Filing, 10-K, Financial Report, Going Concern, Capital Raise, Israel Conflict, Nasdaq